Lineage Cell Therapeutics (LCTX) Cash & Current Investments (2010 - 2026)

Lineage Cell Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $62.7 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 30.92% year-over-year to $62.7 million; the TTM figure through Mar 2026 stood at $62.7 million (up 30.92% YoY), while the FY2025 annual figure was $61.0 million, up 41.64% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $62.7 million, up from $61.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $79.9 million in Q1 2022, with the low at $30.0 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $45.9 million (2023), against an average of $49.7 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments plunged 48.19% in 2023, then surged 43.52% in 2024.
• Lineage Cell Therapeutics' Cash & Current Investments stood at $57.9 million in 2022, then slumped by 48.19% to $30.0 million in 2023, then jumped by 43.52% to $43.0 million in 2024, then surged by 41.64% to $61.0 million in 2025, then advanced by 2.89% to $62.7 million in 2026.
• Business Quant data shows LCTX's Cash & Current Investments at $62.7 million in Q1 2026, $61.0 million in Q4 2025, and $32.2 million in Q3 2025.